Abstract
The toxicological concern with the potential of tamoxifen to increase the incidence of endometrial cancer or hepatocellular carcinoma mandated a new approach to chemoprevention. The SERM raloxifene does not have the toxicological concern of tamoxifen and is approved for the treatment and prevention of osteoporosis but at the same time reduces breast cancer incidence. The Study of Tamoxifen and Raloxifene (STAR) demonstrated that the two SERMs were equivalent in reducing breast cancer incidence but raloxifene had a better safety profile. However, tamoxifen can reduce breast cancer incidence during therapy for 5 years, and this is maintained for at least a decade after treatment. In contrast, raloxifene must be given continuously.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727–2741
Freedman AN, Yu B, Gail MH et al (2011) Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 29:2327–2333
Vogel VG, Costantino JP, Wickerham DL et al (2010) Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 3:696–706
Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467
Jordan VC, Allen KE (1980) Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model. Eur J Cancer 16:239–251
Martino S, Cauley JA, Barrett-Connor E et al (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751–1761
Lacassagne A (1936) Hormonal pathogenesis of adenocarcinoma of the breast. Am J Cancer 27:217–225
Jordan VC (2008) Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 44:30–38
Sporn MB, Dunlop NM, Newton DL, Smith JM (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332–1338
Sporn MB (1976) Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 36:2699–2702
Jordan VC (1976) Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12:419–424
Jordan VC (1974) Antitumour activity of the antiestrogen ICI 46,474 (Tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 5:354
Lerner LJ, Jordan VC (1990) Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res 50:4177–4189
Black LJ, Sato M, Rowley ER et al (1994) Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 93:63–69
Jordan VC, Gosden B (1983) Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018. Endocrinology 113:463–468
Jordan VC, Gosden B (1983) Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor. J Steroid Biochem 19:1249–1258
Gottardis MM, Jordan VC (1987) Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res 47:4020–4024
EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717
Davies C, Godwin J, Gray R et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784
Cuzick J, Forbes JF, Sestak I et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer – 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272–282
Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652–1662
Powles TJ, Ashley S, Tidy A et al (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283–290
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Basel
About this chapter
Cite this chapter
Maximov, P.Y., McDaniel, R.E., Jordan, V.C. (2013). Tamoxifen and Raloxifene Head to Head: The STAR Trial. In: Tamoxifen. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-0348-0664-0_8
Download citation
DOI: https://doi.org/10.1007/978-3-0348-0664-0_8
Published:
Publisher Name: Springer, Basel
Print ISBN: 978-3-0348-0663-3
Online ISBN: 978-3-0348-0664-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)